Mounjaro vs Zepbound: Same Drug, Two Labels

Mounjaro vs Zepbound comes down to one sentence: it is the same medicine wearing two names. Both are tirzepatide, both are made by Eli Lilly, both start at 2.5 mg once a week and stop at 15 mg. What differs is the use printed on the carton. Mounjaro's label covers type 2 diabetes and, since August 2026, cardiovascular-risk reduction in high-risk adults with type 2 diabetes. Zepbound's covers long-term weight reduction, and moderate-to-severe sleep apnea in adults with obesity. That difference barely shows up in your body. It shows up on your bill.

So if a friend is on one and you were handed the other, you were not given a weaker version. You were given the one whose label matches your diagnosis.

Mounjaro vs Zepbound: what each label actually covers

An indication is just the use a regulator reviewed the evidence for and let the company print on the box. Here is what each box says on the current labels, both revised in August 2026.

Each label was earned separately. Zepbound's weight line came out of SURMOUNT-1, a 72-week study of 2,539 adults with obesity or overweight but not diabetes; average weight change ran from about 15% down on the lowest dose to about 21% on the highest, against about 3% on placebo (Jastreboff et al., NEJM 2022). The sleep-apnea line came from two 52-week trials in 469 adults (Malhotra et al., NEJM 2024), and if that is what brought you here, tirzepatide for sleep apnea goes further into it. For the naming mechanics — why one molecule gets two brands at all — see tirzepatide brand names.

Same molecule, same ladder, same pen

Both labels describe the same climb: 2.5 mg once weekly to start, then steps of 2.5 mg no sooner than every four weeks, up to a ceiling of 15 mg. Mounjaro caps children aged 10 and older at 10 mg. Zepbound's maintenance doses are 5, 10 or 15 mg for weight, and 10 or 15 mg for sleep apnea. Both use the same four-day window for a missed dose, and both come in six strengths across the same set of pens and vials.

That is the practical point. A prescriber moving someone between the two brands is not changing the drug and not restarting anything — the milligrams and the injection are identical. What changes is which reviewed use, and which supply, the prescription runs through.

What changed on both labels in August 2026

As of September 6, 2026, the day this article was written, the newest difference between the two names is a heart line that only Mounjaro carries. The agency's record for Mounjaro shows two efficacy supplements approved on August 27, 2026 (Drugs@FDA, NDA 215866), and the label revised that month now lists a second use: reducing the risk of heart attack, stroke or cardiovascular death in adults with type 2 diabetes who are at high risk of those events (current Mounjaro label, revised 08/2026).

The trial behind it is worth reading plainly. SURPASS-CVOT put 13,299 adults who had both type 2 diabetes and established heart disease on either tirzepatide or dulaglutide — an older weekly injection that already carried a heart indication — and followed them for a median of about four years. About 12 in every 100 people on tirzepatide had a heart attack, stroke or cardiovascular death, against about 13 in every 100 on dulaglutide (hazard ratio 0.92, 95% confidence interval 0.83 to 1.01). The study was designed to show tirzepatide was not worse than the comparator, and that is what it showed (Nicholls et al., NEJM 2025). Deaths from any cause came in at 8.5% versus 10.1%, a difference the label flags as not adjusted for multiple comparisons — interesting, but not the result the trial was built to prove.

Both brands picked up the same new caution that month. The labels now carry a warning about diabetic retinopathy — damage to the small blood vessels at the back of the eye that can come with long-standing diabetes — noting that it can temporarily worsen when blood sugar improves quickly, and that anyone with a history of it should be monitored. Mounjaro's version is written for anyone with that history; Zepbound's for people with type 2 diabetes. It is a monitoring point for the prescriber, and a reason to mention any change in vision at a check-in.

Why the name on the prescription decides what insurance does

Plans do not pay for molecules. They pay for reviewed uses.

A benefit that covers diabetes medication reads Mounjaro's label and finds a diagnosis it recognizes. The same plan may put weight-management drugs in an excluded category altogether — and then Zepbound, the identical molecule at the identical milligrams, is not covered at all. That is how two people taking the same injection end up with bills that differ by four figures.

Prior authorization is where it gets settled in practice: the plan asks the prescriber to document a diagnosis, and the diagnosis has to match the label the plan is reading. Does insurance cover tirzepatide has the current numbers on how often each brand clears that step.

Semaglutide has exactly the same split

If the two-names business feels arbitrary, it is at least consistent across the category. Semaglutide, the other widely prescribed GLP-1 medicine, is sold as Ozempic for type 2 diabetes and as Wegovy for weight management. One molecule, two brands, two labels, the same insurance consequences — semaglutide brand names lays that out.

Which of the two molecules suits a given person is a clinical question, not a ranking. Tirzepatide acts at two receptors and semaglutide at one, and that difference usually matters less than your history, your other medications, and how you get on with either.

Where compounded tirzepatide sits in all this

Neither box. That is the honest answer, and it is the one most worth getting right.

Through Promise, tirzepatide is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation offered here — tirzepatide with vitamin B12 — is not FDA-approved. Compounded medications are not reviewed by the FDA for safety, effectiveness or quality. A compounded preparation is made for one named patient by a licensed U.S. compounding pharmacy after a prescription is written. It is not Mounjaro, it is not Zepbound, and it is not a generic of either. There is more on why compounded tirzepatide is not FDA-approved if the regulatory side is what you are weighing.

None of that closes the door. A licensed provider may still prescribe a compounded formulation when they judge it appropriate for the person in front of them; that decision sits between you and your doctor. A licensed provider reviews every request against your history, and not everyone qualifies.

The labels tell you what was reviewed. They cannot tell you what fits your history, and that is the conversation worth having.